Bridgeway Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Bridgeway Capital Management’s Portfolio TERN Stock Details TERN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,000	Closed	-$633K	–	1310
2026 Q1	$633K	Sell	12,000 -19,000	-61%	-$780K	0.01%	784
2025 Q4	$1.25M	Sell	31,000 -64,000	-67%	-$1.48M	0.03%	657
2025 Q3	$713K	Hold	95,000	–	–	0.02%	750
2025 Q2	$354K	Buy	+95,000	New	+$297K	0.01%	834
2023 Q4	–	Sell	-27,500	Closed	-$138K	–	1415
2023 Q3	$138K	Sell	27,500 -23,200	-46%	-$147K	﹤0.01%	1164
2023 Q2	$444K	Hold	50,700	–	–	0.01%	934
2023 Q1	$600K	Sell	50,700 -42,000	-45%	-$401K	0.02%	843
2022 Q4	$944K	Buy	92,700 +23,200	+33%	+$154K	0.02%	743
2022 Q3	$409K	Buy	69,500 +24,000	+53%	+$89.2K	0.01%	944
2022 Q2	$113K	Sell	45,500 -17,200	-27%	-$34.4K	﹤0.01%	1207
2022 Q1	$186K	Sell	62,700 -32,800	-34%	-$140K	﹤0.01%	1184
2021 Q4	$675K	Buy	+95,500	New	+$795K	0.01%	898

Other funds holding TERN

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Bridgeway Capital Management's TERN Position: Q2 2026 in Review

Bridgeway Capital Management sold out of Terns Pharmaceuticals (TERN) in Q2 2026, closing a stake of 12,000 shares — an estimated $633K sold.

Bridgeway Capital Management first reported a position in TERN in Q4 2021 and held it in 12 quarters. The position peaked at $1.25M in Q4 2025. 1 fund tracked by Wall St. Rank holds TERN as of Q2 2026.

Bridgeway Capital Management reported no remaining Terns Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Bridgeway Capital Management sold 12,000 Terns Pharmaceuticals shares in Q2 2026, an estimated $633K.
Bridgeway Capital Management first reported a position in Terns Pharmaceuticals in Q4 2021 and held it in 12 quarters.
Bridgeway Capital Management's Terns Pharmaceuticals position peaked at $1.25M in Q4 2025.
1 fund tracked by Wall St. Rank held Terns Pharmaceuticals as of Q2 2026.

Based on Bridgeway Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.